Rafaèle Tordjman’s Post

Fantastic to see the role of the microbiome across healthcare (pre-clinical onwards) getting the attention it deserves. There are c. 2m bacterial genes in a adult human gut (vs 23k human genes in total) - it’s important to ‘see’ what they are up to. Thank you to Drug Discovery World for publishing my article, whcih highlights that the scalable technology to generate these insights is now available. #guthealth #crc #ibs #microbiome #microbiomeresearch #ibd #autoimmune

📊 TOP BIOMEDICAL AND GENETICS COMPANIES BY MARKET CAP 🌟 Today, we're diving into the market cap of leading Biomedical and Genetics companies, highlighting their significance in the healthcare industry. 🔝 Here are the top ten Biomedical and Genetics companies by market cap: 1. Amgen 2. Vertex Pharmaceuticals 3. Regeneron 4. Bristol Myers Squibb 5. Gilead Sciences 6. CSL 7. GSK (GlaxoSmithKline) 8. Moderna 9. Biogen 10. BioNTech SE 💡These companies are key players in advancing healthcare and genetics research. #WhySummits #Biomedical #Genetics #Healthcare #MarketCap

#Obesity has now become the most interesting indication to track. While #NovoNordisk is facing supply challenges to meet the demand, reducing the production of Victoza to make more #Ozempic, Lilly is hoping high on the efficacy of #Mounjaro. And the space will become more interesting with two more giants entering the competition. #Pfizer has released the positive results of #danuglipron and now #Roche acquired Carmot Therapeutics. The former two have a #metabolic diseases portfolio and will be at an advantage by capturing significant market share. It will be interesting to watch how Pfizer and Roche will perform in the future. For an analyst, more molecules = more competition = more strategies = more analysis + learning + fun 🙂

Forecast: AI in Drug Discovery Market to Surge with 40.2% CAGR by 2028 Download Sample Report PDF: https://lnkd.in/ddwMvvFz By 2023, the global revenue from AI in drug discovery reached $0.9 billion, with forecasts indicating a rise to $4.9 billion by 2028, driven by a robust 40.2% CAGR. Enterprises operating within this industry: Ridgeline Discovery Biotage Isomorphic Labs Xaira Therapeutics Pioneering Medicines Creative Biolabs SPT Labtech Selvita BDG LifeSciences bit.bio Enable Medicine Gubra Xenon Pharmaceuticals Inc. Aurigene Oncology Limited NUVISAN The Science CRO OSE Immunotherapeutics      NovAliX Enterome Ncardia IRBM     Ardena AQEMIA Hummingbird Bioscience iLoF Light Horse Therapeutics Symeres EpiCypher, Inc. Ardigen Genomics plc Vicinitas Therapeutics Nxera Pharma Cardurion Pharmaceuticals Axol Bioscience Ltd. Optibrium Helix Biostructures Dynamic Biosensors PROTEROS biostructures GmbH Domainex #AIHealthcareTech #BiotechAI #PharmaInnovations #MedicalAIResearch #ArtificialIntelligenceInHealthcare #DrugDiscoveryTrends #BioTechInnovations #PrecisionMedicineTech #FutureOfBiotech #MedicalTechInnovation #AIForDrugDiscovery #PharmaTechTrends #BioinformaticsInMedicine #AIandBiotech #HealthcareTechnology #DrugDiscoveryRevolution #PharmaAI #TechInPharma #AIInBiotech #MedicalScienceAI

🌐 Thrilled to have participated in the amazing #OTS2023 Clinical session! Marked by a series of firsts for delivery, pioneering advancements, target engagement and potential therapeutic efficacy. 🌟 The future is clear: Patients will undoubtedly benefit from new groundbreaking oligonucleotide therapies. The question is not 'if,' but 'when' we'll witness these transformative advances! Oligonucleotide Therapeutics Society #OTS #OTSMeeting #OligoMeeting #OTS23 #Research #science #oligonucleotides #oligonucleotidetherapies #oligonucleotidestherapeutics #oligotherapeutics #oligo #pharma #pharamaceutical #RNAdelivery #RNAtherapeutics #RNAdelivery #RNAtherapies #therapeutics #drugdiscovery #biotech #biotechnology #AdvancedTherapies #GlobalHealth #RareDiseases #NATA #Healthcare #Impact #Industry #Innovation #AdvancedTherapies #biochem #Biomedical #biopharma #biotech #biotechnology #clinicalresearch #drugdesign #drugdevelopment #drugdiscovery #genomics #GeneTherapy #health #HealthcareInnovation #LifeScience #Medicine #PrecisionMedicine #RareDisease #nucleotides

We are excited to start into 2024, excited to continue our work on #RadioDARPins with our colleagues from POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company 😊 It is great to see the progress in the field of #radiopharmaceuticals and the new partnerships that are being formed to create synergy. A vibrant field, that is about to bring more and more benefit for patients! We strongly believe that #DARPins will play their part in this, especially trough harnessing their small size (assuring good tumor penetration and fast clearance from healthy tissue) and very high stability (enabling rapid loading with radionuklides) (https://lnkd.in/eNzjemRP). Through our work at Athebio AG, and of course also through the great progress made by Molecular Partners and their partners Novartis and Orano Med, we can assure that the field can build on the huge potential of the #DARPin technology for truly innovative and useful drugs. Cheers to 2024!     #Athebio   #drugdevelopment

Exciting Advances in Aptamer Research! Aptamers, versatile biomolecules with high specificity, are revolutionizing drug discovery and development. The fusion of aptamers with various drug molecules, known as Aptamer-Biomolecule Conjugates, has unlocked a new era in therapeutics. These smart conjugates enable precise targeting of disease-specific markers, reducing off-target effects and enhancing drug efficacy. #Aptamers #DrugDiscovery #Therapeutics #Biotechnology #Innovation #Research #Bioconjugates #PrecisionMedicine #Biomolecules #HealthcareAdvances. This groundbreaking synergy between aptamers and drug development holds immense promise for personalized medicine, making treatments more effective and minimizing side effects. Stay tuned for exciting developments in this field! 👩🔬🔬🧬💊

“CARA is easy to use and reliable, and we appreciate the helpful support when looking to resolve any questions or explore enhancement opportunities”. Find out how multinational biotechnology company Biogen leveraged the functionality and configurability of the CARA Life Sciences Platform to improve their regulatory submission process. Read our case study here : https://lnkd.in/e669PkKW To find out how we can improve your regulatory processes, visit our website : https://lnkd.in/eHDkDR-N #CARAsuccess #CARALifeSciencesPlatform #customersuccess #regulatorysubmissions

Simcere Links Up with Connect, Pays $21M Cash for Rights to Eczema Asset in China    Simcere Pharmaceutical Group Pharmaceutical has entered into an exclusive licensing agreement with Connect Biopharma, securing the rights to develop and commercialize Connect’s monoclonal antibody, rademikibart, for the treatment of certain inflammatory diseases in Greater China. Simcere will pay Connect $21 million upfront and up to $120 million in potential milestone payments.     The deal includes rights to rademikibart in mainland China, Hong Kong, Macau, and Taiwan. Simcere will oversee the completion of rademikibart’s ongoing clinical trials in China for atopic dermatitis, with plans to submit a new drug application by the end of the first quarter of 2024. Connect retains rights to develop and commercialize the antibody in all other markets. Rademikibart aims to offer convenient dosing and improved sustained efficacy for patients with eczema, as indicated by long-term data from a pivotal trial showing sustained responses in the majority of initial responders.    Link to Full Article: https://lnkd.in/exBVGMPC   #innovation #business #lifescience #biopharma #healthcare #global #regional #collaboration #crossborder #jointventure #investing #biothechnology #bitech #phamaceuticals #capitalmarket #stockmarket #venturecapital #fundraising #globaltrade #economy #economics #creativity #technology #raredisease #drugdevelopment #drugdiscovery #pharmaindustry #biopharmaceutical #mentalhealth #oncology #nuerology #cns #autoimmune #endocrinology #cardiovascular #immunology #gynecology #pulmonology #gastroenterology #anesthesiology #urology #cardiovascular #china #japan #korea #israel #latinameica #australia #europe #usa #shanghai #EczemaTreatment #MonoclonalAntibody #ClinicalTrials #GlobalHealth #MedicalResearch 

SFBN Feed: STAT+: Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion https://lnkd.in/g-9MFFGC The booming obesity market is attracting another player, as Roche said Monday it was acquiring Carmot Therapeutics and its weight loss drug candidates for $2.7 billion.  Click here to view original post #BayArea #SanFrancisco #Biotech #Lifescience #News